ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
82.40
+0.22 (0.27%)
At close: Dec 26, 2025, 4:00 PM EST
82.41
+0.01 (0.01%)
After-hours: Dec 26, 2025, 5:24 PM EST
ANI Pharmaceuticals Revenue
ANI Pharmaceuticals had revenue of $227.81M in the quarter ending September 30, 2025, with 53.58% growth. This brings the company's revenue in the last twelve months to $826.88M, up 48.87% year-over-year. In the year 2024, ANI Pharmaceuticals had annual revenue of $614.38M with 26.20% growth.
Revenue (ttm)
$826.88M
Revenue Growth
+48.87%
P/S Ratio
1.97
Revenue / Employee
$921,828
Employees
897
Market Cap
1.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 614.38M | 127.56M | 26.20% |
| Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
| Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
| Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
| Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
| Dec 31, 2019 | 206.55M | 4.97M | 2.47% |
| Dec 31, 2018 | 201.58M | 24.73M | 13.99% |
| Dec 31, 2017 | 176.84M | 48.22M | 37.49% |
| Dec 31, 2016 | 128.62M | 52.30M | 68.53% |
| Dec 31, 2015 | 76.32M | 20.35M | 36.36% |
| Dec 31, 2014 | 55.97M | 25.89M | 86.06% |
| Dec 31, 2013 | 30.08M | 9.71M | 47.67% |
| Dec 31, 2012 | 20.37M | 19.94M | 4,581.27% |
| Dec 31, 2011 | 435.16K | -2.04M | -82.41% |
| Dec 31, 2010 | 2.47M | 1.22M | 96.67% |
| Dec 31, 2009 | 1.26M | -2.52M | -66.73% |
| Dec 31, 2008 | 3.78M | 3.29M | 666.82% |
| Dec 31, 2007 | 493.05K | -13.95M | -96.59% |
| Dec 31, 2006 | 14.44M | 14.18M | 5,488.76% |
| Dec 31, 2005 | 258.35K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANIP News
- 24 days ago - ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise - GlobeNewsWire
- 25 days ago - ANI Pharmaceuticals Announces Board Transition - GlobeNewsWire
- 4 weeks ago - ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London - GlobeNewsWire
- 7 weeks ago - ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates - Seeking Alpha
- 2 months ago - ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET - GlobeNewsWire